Loading article…
NMD Pharma’s Phase 2a ignaceclant trial in Charcot‑Marie‑Tooth shows functional gains and safety, presented June 14 2026 at the PNS meeting.
NMD Pharma announced that its Phase 2a SYNAPSE‑CMT study of ignaceclant demonstrated consistent functional improvements and was well tolerated, with data presented in a late‑breaking oral session at the 2026 Peripheral Neuroscience Association Annual Meeting in Maastricht【2】. The findings matter because there are currently no FDA‑approved therapies for Charcot‑Marie‑Tooth (CMT), a hereditary neuropathy affecting muscle strength and daily function.
| At a glance | |
|---|---|
| Study size | 81 adult CMT patients |
| Treatment duration | 21 days (follow‑up to day 28) |
| Primary endpoint | No difference on 6‑minute walk test |
| Secondary endpoints | Improvements in CMT‑FOM, hand‑grip strength, 9‑hole peg test, patient‑reported outcomes |
| Safety | All adverse events mild/moderate; no serious events or discontinuations |
The double‑blind, placebo‑controlled trial enrolled genetically confirmed CMT1 or CMT2 patients across the US and Europe. While the pre‑specified primary endpoint—change in the 6‑minute walk test at day 21—was not met, secondary measures showed statistically significant gains. Hand‑grip strength improved by day 21 (p = 0.02) and further by day 28 (p < 0.01) versus placebo, and the composite CMT‑Functional Outcome Measure (CMT‑FOM) showed separation from placebo as early as day 7, persisting through day 28【2】. Trends toward better performance were also observed in the 9‑hole peg test and the 10‑meter walk/run test.
Ignaceclant was reported as safe and well tolerated; all adverse events were mild or moderate, with no serious events or treatment discontinuations【2】. The safety observations align with earlier Phase 2a data in generalized myasthenia gravis, where ignaceclant also demonstrated a favorable profile. In January 2025, the U.S. FDA granted orphan‑drug designation for ignaceclant in CMT, underscoring regulatory interest in this unmet‑need area【1】.
The SYNAPSE‑CMT data suggest that short‑term inhibition of the skeletal muscle chloride channel can yield measurable functional benefits in CMT patients, a disease with no approved treatments. Whether longer‑duration studies will amplify these gains and translate into regulatory approval remains the next critical question.
Coverage is mostly measured — 8 of 8 reports stay neutral.
Every Monday — the token unlocks, Fed dates & catalysts set to move crypto and markets this week. So you’re never blindsided.
Free · 3-min read · one-click unsubscribe
AI-assisted synthesis by the TrendWatcher Editorial Desk · sourced from 2 outlets · Jun 18, 2026 · How we report
A report by trustee Jelena McWilliams indicates an $85 million discrepancy between the $265 million in customer balances and the $180 million held by partner banks, but the exact source of the missing funds is still unknown.
More than 100,000 customers of various fintech companies that used Synapse have been locked out of their savings accounts.
The trial showed consistent signals of benefit in functional endpoints, including improved hand grip strength and motor function, with effects persisting up to seven days after treatment ended.
Ignaseclant was reported as well tolerated, with all adverse events classified as mild or moderate and no serious adverse events or discontinuations.
NMD Pharma plans to conduct larger and longer-term studies to further evaluate ignaseclant’s efficacy and safety in Charcot‑Marie‑Tooth disease.